PubMed:15814824
Annnotations
Glycosmos6-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1011-1019 | http://purl.obolibrary.org/obo/MAT_0000491 | denotes | proximal |
uniprot-human
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 28-32 | http://www.uniprot.org/uniprot/Q9BXA4 | denotes | MUC1 |
| T2 | 187-191 | http://www.uniprot.org/uniprot/Q9BXA4 | denotes | MUC1 |
| T3 | 404-408 | http://www.uniprot.org/uniprot/Q9BXA4 | denotes | MUC1 |
| T4 | 795-799 | http://www.uniprot.org/uniprot/Q9BXA4 | denotes | MUC1 |
| T5 | 1214-1218 | http://www.uniprot.org/uniprot/Q9BXA4 | denotes | MUC1 |
| T6 | 1615-1619 | http://www.uniprot.org/uniprot/Q9BXA4 | denotes | MUC1 |
| T7 | 703-712 | http://www.uniprot.org/uniprot/Q10472 | denotes | GalNAc-T1 |
| T8 | 710-712 | http://www.uniprot.org/uniprot/P42765 | denotes | T1 |
| T9 | 1122-1124 | http://www.uniprot.org/uniprot/P42765 | denotes | T1 |
| T10 | 710-712 | http://www.uniprot.org/uniprot/Q01638 | denotes | T1 |
| T11 | 1122-1124 | http://www.uniprot.org/uniprot/Q01638 | denotes | T1 |
| T12 | 710-712 | http://www.uniprot.org/uniprot/Q9BQA2 | denotes | T1 |
| T13 | 1122-1124 | http://www.uniprot.org/uniprot/Q9BQA2 | denotes | T1 |
| T14 | 717-726 | http://www.uniprot.org/uniprot/Q10471 | denotes | GalNAc-T2 |
| T15 | 724-726 | http://www.uniprot.org/uniprot/P24752 | denotes | T2 |
| T16 | 1044-1046 | http://www.uniprot.org/uniprot/P24752 | denotes | T2 |
| T17 | 1258-1260 | http://www.uniprot.org/uniprot/Q96DQ5 | denotes | DT |
| T18 | 1358-1360 | http://www.uniprot.org/uniprot/Q96DQ5 | denotes | DT |
| T19 | 1258-1260 | http://www.uniprot.org/uniprot/P40126 | denotes | DT |
| T20 | 1358-1360 | http://www.uniprot.org/uniprot/P40126 | denotes | DT |
| T21 | 1827-1830 | http://www.uniprot.org/uniprot/Q99075 | denotes | DTR |
uniprot-mouse
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 703-712 | http://www.uniprot.org/uniprot/O08912 | denotes | GalNAc-T1 |
| T2 | 710-712 | http://www.uniprot.org/uniprot/P14719 | denotes | T1 |
| T3 | 1122-1124 | http://www.uniprot.org/uniprot/P14719 | denotes | T1 |
| T4 | 717-726 | http://www.uniprot.org/uniprot/Q6PB93 | denotes | GalNAc-T2 |
| T5 | 724-726 | http://www.uniprot.org/uniprot/Q06666 | denotes | T2 |
| T6 | 1044-1046 | http://www.uniprot.org/uniprot/Q06666 | denotes | T2 |
| T7 | 963-966 | http://www.uniprot.org/uniprot/Q08761 | denotes | Pro |
| T8 | 1258-1260 | http://www.uniprot.org/uniprot/P29812 | denotes | DT |
| T9 | 1358-1360 | http://www.uniprot.org/uniprot/P29812 | denotes | DT |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 174-180 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
| T2 | 285-291 | http://purl.bioontology.org/ontology/NCBITAXON/6754 | denotes | cancer |
| T3 | 843-848 | http://purl.bioontology.org/ontology/STY/T025 | denotes | cells |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 92-104 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylated |
| T2 | 599-612 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T3 | 637-650 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T4 | 867-880 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T5 | 1426-1439 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
| T6 | 116-141 | http://purl.obolibrary.org/obo/GO_0002319 | denotes | differential B lymphocyte |
| T7 | 116-141 | http://purl.obolibrary.org/obo/GO_0002329 | denotes | differential B lymphocyte |
| T8 | 116-141 | http://purl.obolibrary.org/obo/GO_0002327 | denotes | differential B lymphocyte |
| T9 | 116-141 | http://purl.obolibrary.org/obo/GO_0002335 | denotes | differential B lymphocyte |
| T10 | 116-141 | http://purl.obolibrary.org/obo/GO_0045577 | denotes | differential B lymphocyte |
| T11 | 116-141 | http://purl.obolibrary.org/obo/GO_0002316 | denotes | differential B lymphocyte |
| T12 | 116-141 | http://purl.obolibrary.org/obo/GO_0002328 | denotes | differential B lymphocyte |
| T13 | 233-257 | http://purl.obolibrary.org/obo/GO_0002922 | denotes | humoral immune responses |
| T14 | 233-257 | http://purl.obolibrary.org/obo/GO_0002921 | denotes | humoral immune responses |
| T15 | 233-257 | http://purl.obolibrary.org/obo/GO_0002920 | denotes | humoral immune responses |
| T16 | 233-257 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune responses |
| T17 | 241-257 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune responses |
| T18 | 1623-1627 | http://purl.obolibrary.org/obo/GO_0004617 | denotes | sera |
GO-MF
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1558-1572 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | immunoglobulin |
| T2 | 1839-1846 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
| T3 | 1839-1846 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
| T4 | 1839-1846 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
| T5 | 1839-1846 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
GO-CC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 843-848 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
EDAM-topics
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-8 | http://edamontology.org/topic_0080 | denotes | Sequence |
| T2 | 0-8 | http://edamontology.org/topic_3168 | denotes | Sequence |
| T3 | 0-24 | http://edamontology.org/topic_0157 | denotes | Sequence-variant repeats |
| T4 | 157-162 | http://edamontology.org/topic_2815 | denotes | human |
| T5 | 174-180 | http://edamontology.org/topic_2640 | denotes | cancer |
| T6 | 285-291 | http://edamontology.org/topic_2640 | denotes | cancer |
| T7 | 338-346 | http://edamontology.org/topic_0080 | denotes | sequence |
| T8 | 338-346 | http://edamontology.org/topic_3168 | denotes | sequence |
| T9 | 338-362 | http://edamontology.org/topic_0157 | denotes | sequence-variant repeats |
| T10 | 474-487 | http://edamontology.org/topic_0804 | denotes | immunological |
| T11 | 563-571 | http://edamontology.org/topic_3168 | denotes | sequence |
| T12 | 563-571 | http://edamontology.org/topic_0080 | denotes | sequence |
| T13 | 563-587 | http://edamontology.org/topic_0157 | denotes | sequence-variant repeats |
| T14 | 743-761 | http://edamontology.org/topic_3520 | denotes | mass spectrometric |
| T15 | 743-761 | http://edamontology.org/topic_0134 | denotes | mass spectrometric |
| T16 | 800-806 | http://edamontology.org/topic_0632 | denotes | probes |
| T17 | 1337-1345 | http://edamontology.org/topic_0154 | denotes | peptides |
| T18 | 1363-1371 | http://edamontology.org/topic_0154 | denotes | peptides |
| T19 | 1512-1518 | http://edamontology.org/topic_2815 | denotes | humans |
| T20 | 1831-1838 | http://edamontology.org/topic_0154 | denotes | peptide |
EDAM-DFO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-8 | http://edamontology.org/data_2044 | denotes | Sequence |
| T2 | 0-8 | http://edamontology.org/operation_3218 | denotes | Sequence |
| T3 | 0-16 | http://edamontology.org/data_3498 | denotes | Sequence-variant |
| T4 | 326-334 | http://edamontology.org/operation_3432 | denotes | clusters |
| T5 | 338-346 | http://edamontology.org/data_2044 | denotes | sequence |
| T6 | 338-346 | http://edamontology.org/operation_3218 | denotes | sequence |
| T7 | 338-354 | http://edamontology.org/data_3498 | denotes | sequence-variant |
| T8 | 459-469 | http://edamontology.org/data_0883 | denotes | structural |
| T9 | 488-496 | http://edamontology.org/data_1255 | denotes | features |
| T10 | 563-571 | http://edamontology.org/operation_3218 | denotes | sequence |
| T11 | 563-571 | http://edamontology.org/data_2044 | denotes | sequence |
| T12 | 563-579 | http://edamontology.org/data_3498 | denotes | sequence-variant |
| T13 | 614-622 | http://edamontology.org/data_2042 | denotes | Evidence |
| T14 | 743-761 | http://edamontology.org/data_2536 | denotes | mass spectrometric |
| T15 | 1337-1345 | http://edamontology.org/data_2906 | denotes | peptides |
| T16 | 1363-1371 | http://edamontology.org/data_2906 | denotes | peptides |
| T17 | 1709-1717 | http://edamontology.org/operation_3432 | denotes | clusters |
| T18 | 1831-1838 | http://edamontology.org/data_2906 | denotes | peptide |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 15814824-9#108#111#gene1839 | 1827-1830 | gene1839 | denotes | DTR |
| 15814824-9#108#111#gene286187 | 1827-1830 | gene286187 | denotes | DTR |
| 15814824-9#47#61#diseaseC0001418 | 1766-1780 | diseaseC0001418 | denotes | adenocarcinoma |
| 108#111#gene183947#61#diseaseC0001418 | 15814824-9#108#111#gene1839 | 15814824-9#47#61#diseaseC0001418 | associated_with | DTR,adenocarcinoma |
| 108#111#gene28618747#61#diseaseC0001418 | 15814824-9#108#111#gene286187 | 15814824-9#47#61#diseaseC0001418 | associated_with | DTR,adenocarcinoma |
GlycoBiology-MAT
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1011-1019 | http://purl.obolibrary.org/obo/MAT_0000491 | denotes | proximal |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| TextSentencer_T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| TextSentencer_T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| TextSentencer_T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| TextSentencer_T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| TextSentencer_T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| TextSentencer_T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| TextSentencer_T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| TextSentencer_T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| TextSentencer_T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
| T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
| T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
GlyTouCan-IUPAC
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| GlycanIUPAC_T1 | 703-709 | "http://rdf.glycoinfo.org/glycan/G23425WZ" | denotes | GalNAc |
| GlycanIUPAC_T2 | 717-723 | "http://rdf.glycoinfo.org/glycan/G23425WZ" | denotes | GalNAc |
| GlycanIUPAC_T3 | 703-709 | "http://rdf.glycoinfo.org/glycan/G02874VH" | denotes | GalNAc |
| GlycanIUPAC_T4 | 717-723 | "http://rdf.glycoinfo.org/glycan/G02874VH" | denotes | GalNAc |
| GlycanIUPAC_T5 | 703-709 | "http://rdf.glycoinfo.org/glycan/G99699DW" | denotes | GalNAc |
| GlycanIUPAC_T6 | 717-723 | "http://rdf.glycoinfo.org/glycan/G99699DW" | denotes | GalNAc |
| GlycanIUPAC_T7 | 703-709 | "http://rdf.glycoinfo.org/glycan/G22074RM" | denotes | GalNAc |
| GlycanIUPAC_T8 | 717-723 | "http://rdf.glycoinfo.org/glycan/G22074RM" | denotes | GalNAc |
| GlycanIUPAC_T9 | 703-709 | "http://rdf.glycoinfo.org/glycan/G48535VZ" | denotes | GalNAc |
| GlycanIUPAC_T10 | 717-723 | "http://rdf.glycoinfo.org/glycan/G48535VZ" | denotes | GalNAc |
| GlycanIUPAC_T11 | 703-709 | "http://rdf.glycoinfo.org/glycan/G39738WL" | denotes | GalNAc |
| GlycanIUPAC_T12 | 717-723 | "http://rdf.glycoinfo.org/glycan/G39738WL" | denotes | GalNAc |
| GlycanIUPAC_T13 | 703-709 | "http://rdf.glycoinfo.org/glycan/G42313WU" | denotes | GalNAc |
| GlycanIUPAC_T14 | 717-723 | "http://rdf.glycoinfo.org/glycan/G42313WU" | denotes | GalNAc |
| GlycanIUPAC_T15 | 703-709 | "http://rdf.glycoinfo.org/glycan/G00393CK" | denotes | GalNAc |
| GlycanIUPAC_T16 | 717-723 | "http://rdf.glycoinfo.org/glycan/G00393CK" | denotes | GalNAc |
| GlycanIUPAC_T17 | 703-709 | "http://rdf.glycoinfo.org/glycan/G42649EX" | denotes | GalNAc |
| GlycanIUPAC_T18 | 717-723 | "http://rdf.glycoinfo.org/glycan/G42649EX" | denotes | GalNAc |
| GlycanIUPAC_T19 | 703-709 | "http://rdf.glycoinfo.org/glycan/G46880SB" | denotes | GalNAc |
| GlycanIUPAC_T20 | 717-723 | "http://rdf.glycoinfo.org/glycan/G46880SB" | denotes | GalNAc |
| GlycanIUPAC_T21 | 703-709 | "http://rdf.glycoinfo.org/glycan/G75599IR" | denotes | GalNAc |
| GlycanIUPAC_T22 | 717-723 | "http://rdf.glycoinfo.org/glycan/G75599IR" | denotes | GalNAc |
| GlycanIUPAC_T23 | 703-709 | "http://rdf.glycoinfo.org/glycan/G58985MU" | denotes | GalNAc |
| GlycanIUPAC_T24 | 717-723 | "http://rdf.glycoinfo.org/glycan/G58985MU" | denotes | GalNAc |
| GlycanIUPAC_T25 | 703-709 | "http://rdf.glycoinfo.org/glycan/G92517PO" | denotes | GalNAc |
| GlycanIUPAC_T26 | 717-723 | "http://rdf.glycoinfo.org/glycan/G92517PO" | denotes | GalNAc |
| GlycanIUPAC_T27 | 703-709 | "http://rdf.glycoinfo.org/glycan/G88512YL" | denotes | GalNAc |
| GlycanIUPAC_T28 | 717-723 | "http://rdf.glycoinfo.org/glycan/G88512YL" | denotes | GalNAc |
| GlycanIUPAC_T29 | 703-709 | "http://rdf.glycoinfo.org/glycan/G41473NX" | denotes | GalNAc |
| GlycanIUPAC_T30 | 717-723 | "http://rdf.glycoinfo.org/glycan/G41473NX" | denotes | GalNAc |
| GlycanIUPAC_T31 | 703-709 | "http://rdf.glycoinfo.org/glycan/G71089RB" | denotes | GalNAc |
| GlycanIUPAC_T32 | 717-723 | "http://rdf.glycoinfo.org/glycan/G71089RB" | denotes | GalNAc |
| GlycanIUPAC_T33 | 703-709 | "http://rdf.glycoinfo.org/glycan/G73485GZ" | denotes | GalNAc |
| GlycanIUPAC_T34 | 717-723 | "http://rdf.glycoinfo.org/glycan/G73485GZ" | denotes | GalNAc |
| GlycanIUPAC_T35 | 703-709 | "http://rdf.glycoinfo.org/glycan/G61406KC" | denotes | GalNAc |
| GlycanIUPAC_T36 | 717-723 | "http://rdf.glycoinfo.org/glycan/G61406KC" | denotes | GalNAc |
| GlycanIUPAC_T37 | 703-709 | "http://rdf.glycoinfo.org/glycan/G34412GZ" | denotes | GalNAc |
| GlycanIUPAC_T38 | 717-723 | "http://rdf.glycoinfo.org/glycan/G34412GZ" | denotes | GalNAc |
| GlycanIUPAC_T39 | 703-709 | "http://rdf.glycoinfo.org/glycan/G67209FP" | denotes | GalNAc |
| GlycanIUPAC_T40 | 717-723 | "http://rdf.glycoinfo.org/glycan/G67209FP" | denotes | GalNAc |
| GlycanIUPAC_T41 | 703-709 | "http://rdf.glycoinfo.org/glycan/G61442IL" | denotes | GalNAc |
| GlycanIUPAC_T42 | 717-723 | "http://rdf.glycoinfo.org/glycan/G61442IL" | denotes | GalNAc |
| GlycanIUPAC_T43 | 703-709 | "http://rdf.glycoinfo.org/glycan/G93729MV" | denotes | GalNAc |
| GlycanIUPAC_T44 | 717-723 | "http://rdf.glycoinfo.org/glycan/G93729MV" | denotes | GalNAc |
| GlycanIUPAC_T45 | 703-709 | "http://rdf.glycoinfo.org/glycan/G92144AE" | denotes | GalNAc |
| GlycanIUPAC_T46 | 717-723 | "http://rdf.glycoinfo.org/glycan/G92144AE" | denotes | GalNAc |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 187-191 | gene:4582 | denotes | MUC1 |
| T1 | 285-291 | disease:C1306459 | denotes | cancer |
| T2 | 187-191 | gene:4582 | denotes | MUC1 |
| T3 | 285-291 | disease:C0006826 | denotes | cancer |
| T4 | 187-191 | gene:4582 | denotes | MUC1 |
| T5 | 174-180 | disease:C0006826 | denotes | cancer |
| T6 | 187-191 | gene:4582 | denotes | MUC1 |
| T7 | 174-180 | disease:C1306459 | denotes | cancer |
| T8 | 1827-1830 | gene:286187 | denotes | DTR |
| T9 | 1766-1780 | disease:C0001418 | denotes | adenocarcinoma |
| T10 | 1827-1830 | gene:1839 | denotes | DTR |
| T11 | 1766-1780 | disease:C0001418 | denotes | adenocarcinoma |
| R1 | T0 | T1 | associated_with | MUC1,cancer |
| R2 | T2 | T3 | associated_with | MUC1,cancer |
| R3 | T4 | T5 | associated_with | MUC1,cancer |
| R4 | T6 | T7 | associated_with | MUC1,cancer |
| R5 | T8 | T9 | associated_with | DTR,adenocarcinoma |
| R6 | T10 | T11 | associated_with | DTR,adenocarcinoma |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 174-180 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
| T2 | 285-291 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
| T3 | 1766-1780 | Disease | denotes | adenocarcinoma | http://purl.obolibrary.org/obo/MONDO_0004970 |
Glycan-GlyCosmos
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 703-709 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
| T2 | 717-723 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
GlyCosmos15-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 174-180 | Phenotype | denotes | cancer | HP:0002664 |
| T2 | 285-291 | Phenotype | denotes | cancer | HP:0002664 |
GlyCosmos15-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 157-162 | OrganismTaxon | denotes | human | 9606 |
GlyCosmos15-CL
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 129-141 | Cell | denotes | B lymphocyte | http://purl.obolibrary.org/obo/CL:0000236 |
| T2 | 131-141 | Cell | denotes | lymphocyte | http://purl.obolibrary.org/obo/CL:0000542 |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| TextSentencer_T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| TextSentencer_T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| TextSentencer_T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| TextSentencer_T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| TextSentencer_T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| TextSentencer_T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| TextSentencer_T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| TextSentencer_T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| TextSentencer_T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
| T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
| T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
GlyCosmos15-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-152 | Sentence | denotes | Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. |
| T2 | 153-301 | Sentence | denotes | The human epithelial cancer mucin MUC1 is able to break tolerance and to induce humoral immune responses in healthy subjects and in cancer patients. |
| T3 | 302-510 | Sentence | denotes | We recently showed that clusters of sequence-variant repeats are interspersed in the repeat domain of MUC1 at high frequency, which should contribute to the structural and immunological features of the mucin. |
| T4 | 511-613 | Sentence | denotes | Here we elucidated the potential effects exerted by sequence-variant repeats on their O-glycosylation. |
| T5 | 614-958 | Sentence | denotes | Evidence from in vitro glycosylation with polypeptide N-acetylgalactosaminyltransferases GalNAc-T1 and GalNAc-T2 in concert with mass spectrometric analyses of in vivo glycosylated MUC1 probes from transiently transfected HEK293 cells indicated reduced glycosylation densities of repeats with three concerted replacements: AHGVTSAPESRPAPGSTAPA. |
| T6 | 959-1166 | Sentence | denotes | The Pro to Ala replacement in STAPA exerts not only proximal effects on the ppGalNAc-T2 preferred site at -3 and -4, but also more distant effects on the ppGalNAc-T1 preferred site at -15 (TSAPESRPAPGSTAPA). |
| T7 | 1167-1372 | Sentence | denotes | We also examined the conformational changes of MUC1 glycopeptides induced by the concerted DT to ES replacements and revealed a higher conformational flexibility of ES/P peptides compared to DT/P peptides. |
| T8 | 1373-1519 | Sentence | denotes | Differences in conformational flexibilities and in O-glycosylation densities could underlie the observed differential humoral responses in humans. |
| T9 | 1520-1718 | Sentence | denotes | We were able to show that the natural immunoglobulin G (IgG) responses to the repeat domain of MUC1 in sera from nonmalignant control subjects are preferentially directed to variant repeat clusters. |
| T10 | 1719-1847 | Sentence | denotes | In contrast, the IgG response in patients with adenocarcinoma shifted to higher frequencies of preferential DTR peptide binding. |
GlyCosmos15-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 174-180 | Disease | denotes | cancer | MONDO:0004992 |
| T2 | 285-291 | Disease | denotes | cancer | MONDO:0004992 |
| T3 | 1766-1780 | Disease | denotes | adenocarcinoma | MONDO:0004970 |
GlyCosmos15-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 129-141 | Body_part | denotes | B lymphocyte | http://purl.obolibrary.org/obo/CL_0000236 |
GlyCosmos15-FMA
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 129-141 | Body_part | denotes | B lymphocyte | FMA:62869 |
GlyCosmos15-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 1011-1019 | Body_part | denotes | proximal | http://purl.obolibrary.org/obo/MAT_0000491 |
GlyCosmos15-Glycan
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 703-709 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
| T2 | 717-723 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue | db_id |
|---|---|---|---|---|---|
| T1 | 157-162 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 129-141 | Body_part | denotes | B lymphocyte | http://purl.obolibrary.org/obo/CL_0000236 |
Anatomy-MAT
| Id | Subject | Object | Predicate | Lexical cue | mat_id |
|---|---|---|---|---|---|
| T1 | 1011-1019 | Body_part | denotes | proximal | http://purl.obolibrary.org/obo/MAT_0000491 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 174-180 | Phenotype | denotes | cancer | HP:0002664 |
| T2 | 285-291 | Phenotype | denotes | cancer | HP:0002664 |
CL-cell
| Id | Subject | Object | Predicate | Lexical cue | cl_id |
|---|---|---|---|---|---|
| T1 | 129-141 | Cell | denotes | B lymphocyte | http://purl.obolibrary.org/obo/CL:0000236 |
| T2 | 131-141 | Cell | denotes | lymphocyte | http://purl.obolibrary.org/obo/CL:0000542 |